MedTrace Logo

AZD2066 Neuropathic Pain - Mechanical Hypersensitivity

NCT00939094 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2012-09-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate if 28 days of treatment with AZD2066 compared to placebo can relieve the pain arising from the nervous system when the patients are touched by something that should not cause pain or have severe pain when they are touched by something that should only cause a little pain.

Conditions

  • Neuropathic Pain
  • Mechanical Hypersensitivity

Interventions

DRUG

AZD2066

Capsule, once daily

DRUG

Placebo

Capsule, once daily

Sponsors & Collaborators

  • Quintiles, Inc.

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Biljana Lilja · AstraZeneca R&D Södertälje151 85 Södertälje, Sweden

  • Brett Stacey · Oregon Health and Science University Comprehensive Pain Clinic, Portland, OR 97239, USA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00939094 on ClinicalTrials.gov